VivoSeq
Musculoskeletal

Shoulder Pain

44

Pipeline Programs

8

Active Trials

24

Companies Involved

Shoulder pain is a moderately active landscape with 44 programs across 24 companies. The most active players are Revance Therapeutics, Inc., Hope Pharmaceuticals, Hisamitsu Pharmaceutical Co., Inc.. 27 therapies are approved with 3 more in late-stage development.

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

22/100

Mech. Concentration

12/100

Completion Rate

83/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

54

clinical trials

Completed29 · 54%
Unknown status11 · 20%
Not yet recruiting4 · 7%
Terminated4 · 7%
Recruiting3 · 6%
Withdrawn2 · 4%
Other1 · 2%

Trial Activity

54 trials

Exparel for Total Shoulder Pain
Not yet recruiting·UUniversity of South Florida·Phase 2/3·NCT03739021·60 enrolled
Can Parecoxib Reduce Post-operative Ipsilateral Shoulder Pain?
Completed··Phase 2·NCT01288924·160 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)